Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.
- DOI
- 10.3389/fimmu.2022.961926
- Published
- 2022
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2022.961926,
title = {Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.},
author = {Zhou JG and Wong AH and Wang H and Jin SH and Tan F and Chen YZ and He SS and Shen G and Frey B and Fietkau R and Hecht M and Carr SR and Wang R and Shen B and Schrump DS and Ma H and Gaipl US},
year = {2022},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2022.961926},
url = {https://doi.org/10.3389/fimmu.2022.961926}
}RIS
TY - JOUR TI - Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. AU - Zhou JG AU - Wong AH AU - Wang H AU - Jin SH AU - Tan F AU - Chen YZ AU - He SS AU - Shen G AU - Frey B AU - Fietkau R AU - Hecht M AU - Carr SR AU - Wang R AU - Shen B AU - Schrump DS AU - Ma H AU - Gaipl US PY - 2022 JO - Frontiers in immunology DO - 10.3389/fimmu.2022.961926 UR - https://doi.org/10.3389/fimmu.2022.961926 ER -
APA
JG, Z., AH, W., H, W., SH, J., F, T., YZ, C., SS, H., G, S., B, F., R, F., M, H., SR, C., R, W., B, S., DS, S., H, M., & US, G. (2022). Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2022.961926
Source records
- pubmed · retrieved 2026-09-25T12:46:59.065Z